- Japan: 530000 people with side effects after receiving the 3rd dose of Pfizer COVID-19 vaccine
- The Lancet: COVID-19 pandemic will end in March?
- Austria becomes EU first country to make COVID-19 vaccine mandatory
- Moderna COVID-19 vaccine: Less breakthrough infections than Pfizer’s
- Viatris recalls Semglee insulin pens due to lack of label risk.
- Biomarkers and prospects for immunotherapy in hepatocellular carcinoma
Lancet: The clinical stage IIb results of the third antibody sonelokimab are excellent. On April 23, Lancet published online detailed clinical phase IIb trial data of the tertiary antibody sonelokimab for the treatment of moderate to severe plaque psoriasis. The primary and secondary endpoints were all met.
Sonelokimab is a trispecific antibody targeting IL17A and IL-17F, developed by Avillion and Merck Serono.
The multi-center, randomized, placebo-controlled Phase IIb clinical trial was carried out in 41 clinical centers in the United States, Germany and other countries or regions. The clinical trial code is NCT03384745.
Investigator’s overall assessment (IGA) week 12 compared with baseline is clinically and statistically significant (p<0.001).
Psoriasis area and severity index (PASI75, PASI90, and PASI100) were also statistically significant compared to baseline at week 12 (p≤0.002).
In terms of safety:
Sonelokimab is similar to Novartis secukinumab except for the Candida infection rate (17.4% VS 1.9%).
Novartis secukinumab is the world’s first monoclonal antibody targeting IL-17A, with global sales of 3.995 billion US dollars in 2020. Sonelokimab has shown rapid onset in phase IIb clinical trials (approximately 1/3 of patients appeared in the 4th week) PASI 90 response), durability, tolerance and other excellent effects, the future phase III clinical is expected to directly carry out a head-to-head trial with secukinumab.
Psoriasis: cited from wikipedia.org:
Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by raised areas of abnormal skin. These areas are red, or purple on some people with darker skin, dry, itchy, and scaly. Psoriasis varies in severity from small, localized patches to complete body coverage. Injury to the skin can trigger psoriatic skin changes at that spot, which is known as the Koebner phenomenon.
The five main types of psoriasis are plaque, guttate, inverse, pustular, and erythrodermic. Plaque psoriasis, also known as psoriasis vulgaris, makes up about 90% of cases. It typically presents as red patches with white scales on top. Areas of the body most commonly affected are the back of the forearms, shins, navel area, and scalp. Guttate psoriasis has drop-shaped lesions…….
(source:internet, reference only)